3 stories in the last 7 days
The latest obesity news, distilled by AI into sharp ~100-word summaries. ByteBrief tracks obesity across dozens of tech sources and brings you only what matters, updated hourly. Tap any story for the full brief, or open the original source.
Eli Lilly's Ken Custer said the obesity market is in its infancy despite millions of patients on these medicines. He noted billions could potentially benefit from the treatments. The scale of what remains to be accomplished surprised him most about the category's development.
Zealand Pharma CEO Adam Steensberg presented at the Goldman Sachs 47th Annual Global Healthcare Conference 2026 on June 9, 2026. Steensberg discussed positive ADA updates for survodutide and petrelintide, noting a shift in obesity treatment focus from maximum tolerated doses toward minimum effective doses.
Novo Nordisk discussed progress in its obesity and diabetes portfolio and pill launch milestones at a June 7, 2026 R&D event. CEO Maziar Doustdar, EVP Martin Lange, and CFO Karsten Knudsen presented. The event included forward-looking statements and a Q&A session.
Summaries by ByteBrief